Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Sol-Gel Technologies Ltd. (SLGL)

BridgeBio Oncology Therapeutics, Inc and Sol-Gel Technologies Ltd. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Sol-Gel Technologies Ltd. are of similar size ($236.5M and $224.9M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (−127.7% vs −6,630.2%). Across the 12 metrics below, BridgeBio Oncology Therapeutics, Inc leads on 7 and Sol-Gel Technologies Ltd. on 5.

Valuation

Metric BBOT SLGL Biotechnology median
P/E n/m n/m 8.50
P/S n/m 117.08 9.71
P/B 0.70 4.37 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 126.78 9.21
Earnings yield (97.87%) (8.78%) (33.15%)
Free cash flow yield (67.14%) (10.12%) (25.50%)

Profitability

Metric BBOT SLGL Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (252.10%) (40.85%) (56.36%)
Return on assets (96.69%) (35.11%) (48.04%)
Return on invested capital (127.66%) (6,630.24%) 0.00%

Growth

Metric BBOT SLGL Biotechnology median
Revenue growth (TTM) — (92.50%) 6.02%
EPS growth (last fiscal year) 99.93% 42.37% 30.26%
Revenue growth, 5-year CAGR — 17.19% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 10.37 4.72
Net debt to EBITDA 2.93 3.23 0.96

Dividend

Metric BBOT SLGL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBOT SLGL Biotechnology median
Market cap 236.52m 224.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack